

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tomoki KATO, et al. :

APPLICATION NO.: 10/597,480 : Examiner: Not Assigned

INT'L FILING DATE: January 18, 2005 : Group Art Unit: 2614

TITLE: 1-Isopropyl-2-oxo-1,2-dihydropyridine-3-
carboxamide Derivatives Having 5-HT₄ Receptor
Agonistic Activity :

Commissioner for Patents
Via EFS

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant(s) hereby bring to the Examiner's attention the documents cited in the attached citation form, copies of which are enclosed (other than cited U.S. patents and U.S. patent publications).

The Examiner is respectfully requested to consider the cited documents in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a) and to indicate such by returning a signed and initialed copy of the citation form and listing the documents in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


No action on the merits has been received and no fee is believed to be due. The Commissioner is authorized to charge any necessary fees or credit any overpayment to Account No. 16-1445.

Should there be any questions, the Examiner is invited to contact the undersigned.

Date:

30 Oct 06

Respectfully submitted,


Frank W. Forman
Attorney for Applicant(s)
Reg. No. 42,547

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5669
frank.w.forman@pfizer.com